Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Sells $10,036.04 in Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Eliana Clark sold 1,022 shares of Intellia Therapeutics stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $9.82, for a total value of $10,036.04. Following the completion of the sale, the executive vice president owned 95,369 shares of the company’s stock, valued at approximately $936,523.58. The trade was a 1.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Intellia Therapeutics Stock Down 0.1%

Shares of NASDAQ:NTLA opened at $10.72 on Friday. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -2.05 and a beta of 2.21. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $28.18. The business’s 50 day moving average is $8.77 and its 200 day moving average is $9.36.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.16. The company had revenue of $16.63 million for the quarter, compared to analysts’ expectations of $11.39 million. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. Intellia Therapeutics’s quarterly revenue was down 42.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.12) earnings per share. As a group, equities research analysts expect that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Ensign Peak Advisors Inc boosted its position in Intellia Therapeutics by 2.9% in the fourth quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock worth $457,000 after purchasing an additional 1,100 shares during the last quarter. HighTower Advisors LLC boosted its position in Intellia Therapeutics by 8.2% in the first quarter. HighTower Advisors LLC now owns 16,921 shares of the company’s stock worth $120,000 after purchasing an additional 1,282 shares during the last quarter. Arizona State Retirement System boosted its position in Intellia Therapeutics by 6.1% in the fourth quarter. Arizona State Retirement System now owns 28,006 shares of the company’s stock worth $327,000 after purchasing an additional 1,615 shares during the last quarter. E Fund Management Co. Ltd. boosted its position in Intellia Therapeutics by 10.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company’s stock worth $210,000 after purchasing an additional 1,634 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its position in Intellia Therapeutics by 56.4% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock worth $33,000 after purchasing an additional 1,655 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Wall Street Analyst Weigh In

NTLA has been the subject of a number of research analyst reports. Canaccord Genuity Group lowered their target price on Intellia Therapeutics from $74.00 to $54.00 and set a “buy” rating for the company in a report on Tuesday, June 3rd. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Intellia Therapeutics in a report on Monday, June 16th. Wedbush reiterated a “neutral” rating and issued a $7.00 target price on shares of Intellia Therapeutics in a report on Monday, June 16th. Chardan Capital reiterated a “buy” rating and issued a $68.00 target price on shares of Intellia Therapeutics in a report on Friday, May 9th. Finally, Wolfe Research upgraded Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 target price for the company in a report on Monday, April 21st. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $33.37.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.